ADC THERAPEUTICS SA |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.34 USD | -2.25% |
|
-8.05% | +161.45% |
| Apr. 09 | Transcript : ADC Therapeutics SA - Special Call | |
| Apr. 04 | Sector Update: Health Care Stocks Slump Late Afternoon | MT |
Valuation
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 2,485 | 1,550 | 306.9 | 134.1 | 358.2 | - | - |
| Enterprise Value (EV) 1 | 2,087 | 1,092 | 90.22 | -20.12 | 416.6 | 411.7 | 358.2 |
| P/E ratio | -8.49 x | -6.73 x | -1.93 x | -0.56 x | -2.02 x | -2.43 x | -3.23 x |
| Yield | - | - | - | - | - | - | - |
| Capitalization / Revenue | - | 45.7 x | 1.46 x | 1.93 x | 4.43 x | 3.8 x | 2.46 x |
| EV / Revenue | - | 32.2 x | 0.43 x | -0.29 x | 5.15 x | 4.37 x | 2.46 x |
| EV / EBITDA | -11,628,787 x | -5,497,765 x | -1,253,468 x | - | - | - | - |
| EV / FCF | - | -4.61 x | -0.66 x | 0.17 x | -3.74 x | -4.62 x | -20 x |
| FCF Yield | - | -21.7% | -152% | 606% | -26.7% | -21.6% | -5% |
| Price to Book | 7.32 x | 9.34 x | 3.49 x | - | - | - | - |
| Nbr of stocks (in thousands) | 77,619 | 76,754 | 79,934 | 80,781 | 82,530 | - | - |
| Reference price 2 | 32.01 | 20.20 | 3.840 | 1.660 | 4.340 | 4.340 | 4.340 |
| Announcement Date | 3/18/21 | 3/3/22 | 2/28/23 | 3/13/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 2.34 | - | 33.92 | 209.9 | 69.56 | 80.92 | 94.29 | 145.7 |
| EBITDA | - | -179.5 | -198.6 | -71.98 | - | - | - | - |
| EBIT 1 | - | -219.3 | -261.7 | -123.6 | -166 | -157.9 | -148.2 | -118.7 |
| Operating Margin | - | - | -771.65% | -58.9% | -238.63% | -195.16% | -157.14% | -81.47% |
| Earnings before Tax (EBT) 1 | - | -246 | -251.5 | -154.7 | -195.4 | -175.5 | -162.1 | -134.9 |
| Net income 1 | - | -246.3 | -230 | -155.8 | -240.1 | -183.1 | -171 | -134.9 |
| Net margin | - | - | -678.2% | -74.22% | -345.11% | -226.22% | -181.32% | -92.52% |
| EPS 2 | -2.360 | -3.770 | -3.000 | -1.990 | -2.940 | -2.150 | -1.785 | -1.342 |
| Free Cash Flow 1 | - | - | -236.8 | -137.4 | -121.9 | -111.2 | -89.05 | -17.9 |
| FCF margin | - | - | -698.2% | -65.44% | -175.25% | -137.47% | -94.44% | -12.28% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 4/24/20 | 3/18/21 | 3/3/22 | 2/28/23 | 3/13/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 13.15 | 17.01 | 46.5 | 17.29 | 76.32 | 69.8 | 18.99 | 19.28 | 14.49 | 16.79 | 18.26 | 19.42 | 20.39 | 20.77 |
| EBITDA | -57.13 | -15.49 | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -57.79 | -62.78 | -40.36 | -69.41 | -3.114 | -10.74 | -51.57 | -39.79 | -37.4 | -39.98 | -39.97 | -39.61 | -39.39 | -39.37 |
| Operating Margin | -439.58% | -369.08% | -86.81% | -401.43% | -4.08% | -15.38% | -271.55% | -206.34% | -258.08% | -238.11% | -218.83% | -203.93% | -193.21% | -189.57% |
| Earnings before Tax (EBT) 1 | -71.4 | -56.35 | -17.83 | -65.32 | -51.32 | -20.19 | -59.69 | -53.73 | -47.89 | -39.87 | -45.14 | -44.92 | -44.74 | -44.87 |
| Net income 1 | -71.55 | -34.38 | -16.66 | -64.37 | -50.61 | -24.16 | -59.43 | -47.12 | -47.81 | -85.03 | -47.54 | -47.32 | -46.74 | -46.87 |
| Net margin | -544.22% | -202.12% | -35.83% | -372.3% | -66.31% | -34.61% | -312.9% | -244.34% | -329.86% | -506.44% | -260.3% | -243.65% | -229.29% | -225.67% |
| EPS 2 | -0.9300 | -0.4500 | -0.2200 | -0.8400 | -0.6500 | -0.3000 | -0.7400 | -0.5800 | -0.5800 | -1.030 | -0.5709 | -0.5665 | -0.5433 | -0.5220 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/2/21 | 3/3/22 | 5/9/22 | 8/9/22 | 11/8/22 | 2/28/23 | 5/9/23 | 8/8/23 | 11/7/23 | 3/13/24 | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | 58.4 | 53.5 | - |
| Net Cash position 1 | - | 397 | 459 | 217 | 154 | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | - | - | -237 | -137 | -122 | -111 | -89.1 | -17.9 |
| ROE (net income / shareholders' equity) | - | -110% | -91.7% | -122% | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | -27.2% | -43.9% | -81.1% | -106% | - |
| Assets 1 | - | - | - | 573.6 | 546.5 | 225.7 | 162 | - |
| Book Value Per Share | - | 4.370 | 2.160 | 1.100 | - | - | - | - |
| Cash Flow per Share | - | -2.580 | - | - | - | - | - | - |
| Capex 1 | - | 0.8 | 3.43 | 0.58 | 3.22 | 2.65 | 2 | 3.1 |
| Capex / Sales | - | - | 10.11% | 0.27% | 4.62% | 3.27% | 2.12% | 2.13% |
| Announcement Date | 4/24/20 | 3/18/21 | 3/3/22 | 2/28/23 | 3/13/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
4.34
USD
Average target price
10.2
USD
Spread / Average Target
+135.02%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +161.45% | 358M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- ADCT Stock
- Financials ADC Therapeutics SA
